Ipca Laboratories Limited
IPCALAB
Rangering i aksjer
#3415
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Aksjekurs
$20.02
Sist synkronisert: 2026-10-19
Markedsverdi
$5.08B
Endring (1 dag)
-1.65%
Endring (1 år)
38.46%
Land
IN
Handel Ipca Laboratories Limited (IPCALAB)
Kategori
Healthcare
Antall utestående aksjer for Ipca Laboratories Limited (IPCALAB)
Antall utestående aksjer per June 2026: 253.70M
Ifølge Ipca Laboratories Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 253.70M. Ved slutten av March 2024 hadde selskapet 253.70M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Ipca Laboratories Limited (IPCALAB) fra 2005 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 253.70M | 0.00% |
| 2025 | 253.70M | 0.00% |
| 2024 | 253.70M | 0.00% |
| 2023 | 253.70M | 0.00% |
| 2022 | 253.70M | 0.17% |
| 2021 | 253.28M | 0.16% |
| 2020 | 252.89M | 0.09% |
| 2019 | 252.65M | 0.09% |
| 2018 | 252.42M | 0.01% |
| 2017 | 252.40M | -0.01% |
| 2016 | 252.41M | 0.01% |
| 2015 | 252.40M | 0.00% |
| 2014 | 252.40M | 0.03% |
| 2013 | 252.32M | 0.08% |
| 2012 | 252.11M | 0.52% |
| 2011 | 250.81M | 0.41% |
| 2010 | 249.79M | -0.51% |
| 2009 | 251.07M | 0.31% |
| 2008 | 250.31M | 0.12% |
| 2007 | 250.00M | 0.00% |
| 2006 | 250.00M | 0.00% |
| 2005 | 250.00M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 845.72% |
IN
|
